Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...

Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836: Lyon, France Saturday, November 16, 2024, 14:00 Hrs [IST] O ...

Vaxart ( (VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...

The non-qualified stock option is an option to purchase 64,150 shares of Novavax's common stock with a per share exercise price of $9.01, the closing price of Novavax's common stock on the Nasdaq ...

In addition, our standalone influenza vaccine program is based on a platform that has demonstrated enhanced immunogenicity in ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by ... using traditional cell culture or recombinant techniques. The 25,000-subject ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024Solid financial position ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...